Recursion Pharmaceuticals, Inc. (RXRX) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Recursion Pharmaceuticals’s revenue went from $2M in fiscal 2019 to $75M in fiscal 2025, growth of about 78.4% a year.
Net income in fiscal 2025 was -$645M, a net margin of -863.4%; the best year in this period was 2019 with -$62M.
Over the twelve months to September 30, 2026, revenue was $68M and net income -$476M.
Free cash flow was -$378M in fiscal 2025 and positive in 0 of the 7 years shown.
The diluted share count rose 1974% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $68M | $75M | $59M | $45M | $40M | $10M | $4M | $2M |
| Gross profit | $20M | $4M | $14M | $2M | -$8M | $10M | $4M | — |
| Operating income | -$495M | -$648M | -$479M | -$350M | -$246M | -$183M | -$85M | -$62M |
| Net income | -$476M | -$645M | -$464M | -$328M | -$239M | -$186M | -$87M | -$62M |
| EPS (diluted) | $-0.86 | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 | $-3.99 | $-2.87 |
| R&D | $373M | $475M | $314M | $241M | $156M | $135M | $63M | $46M |
| Revenue growth | — | +26.9% | +32.0% | +11.9% | +291.5% | +156.9% | +70.9% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$311M | -$372M | -$359M | -$288M | -$84M | -$159M | -$45M | -$57M |
| Capital spending | -$2M | -$6M | -$14M | -$12M | -$37M | -$40M | -$6M | -$4M |
| Free cash flow | -$312M | -$378M | -$373M | -$300M | -$121M | -$198M | -$51M | -$61M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — |
| Stock-based pay | $89M | $111M | $82M | $54M | $28M | $15M | $4M | $1M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $743M | $594M | $392M | $550M | $517M | $262M | $75M |
| Debt | — | $78M | $108M | $51M | $51M | $49M | $12M | — |
| Equity | — | $1.1B | $1.0B | $463M | $486M | $543M | -$206M | -$124M |
| Total assets | — | $1.5B | $1.4B | $654M | $701M | $610M | $299M | — |
| Shares (diluted) | 543M | 447M | 274M | 208M | 176M | 125M | 22M | 22M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 29.2% | 5.0% | 23.1% | 4.5% | -21.2% | 100.0% | 100.0% | — |
| Operating margin | -725.4% | -867.9% | -814.1% | -785.3% | -616.7% | -1795.8% | -2135.7% | -2692.6% |
| Net margin | -697.1% | -863.4% | -788.0% | -736.0% | -601.1% | -1832.2% | -2196.0% | -2668.3% |
| FCF margin | -458.0% | -506.5% | -633.7% | -672.4% | -302.6% | -1949.4% | -1293.0% | -2628.4% |
| ROIC | — | -53.6% | -41.8% | -67.3% | -45.8% | -30.9% | — | — |
| ROE | — | -57.0% | -44.8% | -70.8% | -49.3% | -34.4% | 42.2% | 49.8% |
Frequently asked questions
What is Recursion Pharmaceuticals’s annual revenue?
$75M in fiscal 2025 and $68M over the twelve months to September 30, 2026.
How much profit does Recursion Pharmaceuticals make?
Net income was -$645M in fiscal 2025 (net margin -863.4%).
Is Recursion Pharmaceuticals’s revenue growing?
Yes: revenue rose 26.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.